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Cancer Epidemiology 
NOVELITY AND IMPACT 
In this multi-country prospective cohort analysis, higher predicted BMR was associated with greater 
risk for most cancers that have been linked with obesity. Importantly, among normal-weight 
individuals (BMI<25kg/m2), BMR was positively associated with cancers of the colon, pancreas, 
thyroid, esophageal adenocarcinoma, postmenopausal breast, and endometrium.  These results suggest 
that BMR may identify subgroups of the population who are at greater risk of these malignancies that 
would not have otherwise been identified solely by BMI.   
 
ABSTRACT 
Emerging evidence suggests that a metabolic profile associated with obesity may be a more relevant 
risk factor for some cancers than adiposity per se. Basal metabolic rate (BMR) is an indicator of 
overall body metabolism and may be a proxy for the impact of a specific metabolic profile on cancer 
risk. Therefore, we investigated the association of estimated BMR with incidence of 13 obesity-
related cancers in the European Prospective Investigation into Cancer and Nutrition. Estimated BMR 
at baseline was calculated using the WHO/FAO/UNU equations and the relationships between BMR 
and cancer risk were investigated using multivariable Cox proportional hazards regression models. A 
total of 141,295 men and 317,613 women, with a mean follow-up of 14 years were included in the 
analysis. Overall, higher BMR was associated with a greater risk for most cancers that have been 
linked with obesity. However, among normal weight participants, higher BMR was associated with 
elevated risks of esophageal adenocarcinoma (Hazard Ratio per 1-standard deviation change in BMR 
[HR1-sd]: 2.46; 95%CI 1.20; 5.03), and distal colon cancer (HR1-sd: 1.33; 95%CI 1.001; 1.77) among 
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men, and with proximal colon (HR1-sd: 1.16; 95%CI 1.01; 1.35), pancreatic (HR1-sd: 1.37; 95%CI 1.13; 
1.66), thyroid (HR1-sd: 1.65; 95%CI 1.33; 2.05), postmenopausal breast (HR1-sd: 1.17; 95%CI 1.11; 
1.22), and endometrial (HR1-sd: 1.20; 95%CI 1.03; 1.40) cancers in women. These results indicate that 
higher BMR may be an indicator of a metabolic phenotype associated with risk of certain cancer 
types, and may be a useful predictor of cancer risk independent of body fatness.  
INTRODUCTION 
There is growing consensus that obesity and related metabolic disorders such as Type 2 diabetes 
(T2D) represent important risk factors for a significant number of cancers. According to a recent 
report by the International Agency for Research on Cancer (IARC), there is sufficient evidence for 
obesity to be classified as a causal risk factor for cancers of the esophagus (adenocarcinoma), stomach 
cardia, colorectum, liver, gallbladder, pancreas, breast (postmenopausal), corpus uteri, ovary, kidney, 
meningioma, thyroid and multiple myeloma (1), while T2D is an established risk factor for cancers of 
the colorectum, pancreas, liver, gallbladder, breast, and corpus uteri (2). It has been predicted that at 
least 5.7 % (approximately 804,100 cases) of the global cancer burden in 2012 could be attributed to 
high body mass index (BMI) and T2D combined (3). 
Emerging evidence suggests that metabolic factors which typically accompany obesity, such as 
insulin resistance and hyperinsulinaemia, may be more relevant risk factors for some cancers than 
adiposity per se. For example, in analyses conducted within the European Prospective Investigation 
into Cancer and Nutrition (EPIC) and the Women’s Health Initiative (WHI), participants with higher 
insulin levels were at greater risk of developing colorectal and breast cancer, compared to those with 
normal insulin levels, regardless of body fatness (4-7). These studies indicate that metabolic factors 
such as hyperinsulinemia are an important determinant of some common cancers, independent of 
overall adiposity.  
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Basal metabolic rate (BMR) is defined as the daily rate of energy metabolism required to preserve the 
integrity of vital functions in both waking and resting states (8) and represents 35 to 70% of the total 
energy requirement of an individual. It has been shown that BMR is higher in younger age, in males, 
and in individuals with greater height, weight and lean body mass (9). BMR has also been shown to 
be positively associated with pro-inflammatory status among both normal weight and overweight 
individuals (10), suggesting it may be a marker of metabolic health, independent of adiposity. 
Consistent with this, in a cohort study of elderly individuals, higher BMR was found to be associated 
with greater mortality risk, independent of body mass index (BMI) (11). Similarly, a cohort study of 
Pima Indians found that every 100 kcal increase in daily energy expenditure was associated with 29% 
higher risk of natural death, regardless of participants’ body weight (12).  To date, only one study has 
investigated the association between BMR and cancer risk, and specifically breast cancer, using data 
from the National Health and Nutrition Examination Survey (NHANES) in the United States. That 
study found that postmenopausal women in the upper quintile for BMR had significantly greater 
breast cancer risk compared to those in the lower quintile (13). However, it is currently unknown if 
BMR is associated with risk of other cancers and whether these relationships are independent of 
adiposity.  
We therefore conducted a comprehensive investigation of predicted BMR and its association with the 
risk of 13 cancers in the European Prospective Investigation into Cancer (EPIC) a prospective cohort 
of over 520,000 participants with baseline data on BMR. The large number of recorded incident 
cancer cases afforded sufficient statistical power to investigate the BMR and cancer relationships 
according to sex and by strata of body habitus (normal weight and overweight).  
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The European Prospective Investigation into Cancer and Nutrition (EPIC) is an ongoing multicentre 
prospective cohort study, designed to investigate the associations between diet, lifestyle, genetic and 
environmental factors and various types of cancer. A detailed description of this cohort study has been 
published elsewhere (14, 15). Briefly, a total of 521,324 participants (~70% female) were recruited 
between 1992 and 2000 from 23 centers across ten European countries (Denmark, France, Germany, 
Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom). All study 
participants provided written informed consent. Ethical approval for the EPIC study was obtained 
from the review boards of the International Agency for Research on Cancer and local participating 
centres: National Committee on Health Research Ethics (Denmark); Comité de Protection des 
Personnes (France); Ethics Committee of the Heidelberg University Medical School (Germany); 
Ethikkommission der Landesärztekammer Brandenburg Cottbus (Germany); University of Athens 
Medical School (Greece) Comitato Etico Indipendente, Fondazione IRCCS Istituto Nazionale dei 
Tumori (Italy); Human Genetics Foundation Torino Ethics Committee (Italy); Medical Ethical 
Committee (METC) of the University Medical Center Utrecht (the Netherlands); Regional Ethical 
Committee for Northern Norway and the Norwegian Data Inspectorate (Norway); Comité de Ética de 
Investigación Clínica (Spain); Ethics Committee of Lund University (Sweden); Umea Regional 
Ethical Review Board (Sweden); Norwich District Ethics Committee (UK); Scotland A Research 
Ethics Committee (UK); and the Imperial College Research Ethics Committee (UK). The current 
study included participants with information at baseline on sex, age, weight, and height, which were 
used to compute the basal metabolic rate (BMR). Participants were excluded if they were: pregnant at 
baseline (n=547); had cancer at recruitment (n=25,184); had missing follow-up information 
(n=4,148); had missing baseline questionnaire data (n=6,259); self-reported thyroid disease as this 
may affect individuals’ BMR (n=16,705); or were within the extreme ranking (top and bottom 1%) of 
the ratio energy intake/energy requirement (n=9,573). This cut-off point for the ratio of energy 
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intake/energy requirement is a routine exclusion made on the EPIC baseline questionnaire on all EPIC 
analyses. A more stringent cut-off point (top and bottom 5%) was performed with no change in the 
study results (data not shown). 
Follow-up for Cancer Incidence 
Incident cancer cases were identified using cancer registries in Norway, Sweden, United Kingdom, 
Spain, Italy, the Netherlands, and Denmark. For other countries, such as France, Germany and 
Greece, incident cancer cases were identified during follow-up from a combination of sources 
including cancer and pathology centres, health insurance records and active follow-up of study 
subjects. All countries followed a detailed protocol for the collection and standardization of clinical 
and pathological data on each cancer site (16-19). The end of follow-up was established as the latest 
date of follow-up for cancer incidence, death or end of follow-up, whichever came first. Censoring 
dates for complete follow-up from cancer registries were between December 2009 and December 
2013. Cancer cases were identified using the 10th Revision of the International Classification of 
Diseases (ICD-10) and the 2nd Revision of the International Classification of Diseases for Oncology 
(ICDO-2). In the current analysis we focused on cancers judged to be related to obesity by IARC and 
WCRF (1, 20) : esophageal adenocarcinoma (C150-159), stomach cardia (C160), colon (C180-189), 
rectal (C199-209), liver: hepatocellular carcinoma (220-221), gallbladder (C239), pancreas (C250-
259), breast: premenopausal and postmenopausal (C500-509), endometrium (C540-549), ovarian 
(C569), kidney (C649), meningioma (C700-709), thyroid (C739) and multiple myeloma (C420-424). 
Whenever possible, morphology information was used to classify the malignant tumours according to 
histological type, as for example, esophageal adenocarcinoma and hepatocellular carcinoma. 
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At baseline, information on lifestyle, dietary intake and medical information as well as demographics 
and anthropometric data were collected. Lifestyle and medical history questionnaires were used to 
obtain information on education, smoking status and intensity, alcohol consumption, diabetes and 
women’s health (menopausal status, oral contraceptive use, hormone replacement use, age at 
menarche and age at first full-term pregnancy). Physical activity levels were estimated using a 
questionnaire focused on past-year physical activity in occupational, leisure and household domains 
and classified according to the validated Cambridge physical activity index (21). Validated 
country/centre-specific dietary questionnaires were used to obtain information on dietary intake 
(energy, dietary fibre, fish and shellfish, meat and processed meat intake). The types of dietary 
questionnaires used varied according to the study centre, including semi-quantitative food frequency 
questionnaires (FFQ) with or without an estimation of individual average portion size and diet history 
questionnaires combining a FFQ and 7-day dietary recalls (15). Body weight and height were 
measured in all centres, except for Oxford, France and Norway where these were self- reported. 
Anthropometric characteristics were measured by trained observers using standardized methods (15). 
Body weight was measured by electronic digital scales, with subjects wearing only light underwear 
and after emptying the bladder. Height was measured to the nearest 0.1 cm using a flexible 
anthropometers (22). Assessed weight and height were used to calculate BMI defined as weight in 
kilograms divided by height in metres squared (kg/m2).  
Assessment of predicted Basal Metabolic Rate  
Predicted BMR at baseline was calculated for each participant using the WHO/FAO/UNU (23) 
equations, which are based on Schofield equations (24). This method calculates BMR using gender 
and age-specific equations (18 to 30 years; 31 to 60 years and >60 years) as shown in S1 Table. The 
equations also take into account an individuals’ weight and height. This method is one of the most 
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frequently used to assess BMR in dietary studies and according to the experts of the European Food 
Safety Authority (EFSA), it can be considered as equally valid as those more recently developed (25). 
For comparison, BMR was also assessed using other methods including the Oxford (8), Harris-
Benedict (26) and Mifflin St Jeor (27) equations that also use sex, age, weight and height to predicted 
BMR (S1 Table).  
Statistical Analysis 
Pearson correlation coefficients between BMR defined by WHO/FAO/UNU and the other BMR 
equations were derived. The Pearson correlation coefficients between BMR, BMI, weight and height 
were also assessed. The relationships between BMR and BMI with cancer risk were investigated 
using multivariable Cox proportional hazards regression models (Hazard ratio [HR] and 95% 
confidence intervals [95%CI]). Time at entry was age at recruitment and exit time was age at cancer 
diagnosis, end of follow-up, lost to follow-up or death, whichever came first. Models were stratified 
by country and age at recruitment (in 1-year categories) to control for age and country-specific 
effects. Sex-specific BMR and BMI continuous variables were normalised to 1-standard deviation, in 
order to allow the comparison of the associations of these exposures with cancer risk. Multivariable 
models were adjusted for other cancer risk factors, namely: education (none; primary school; 
technical/professional school; secondary school; and longer education), physical activity index 
(inactive; moderately inactive; moderately active; and active), smoking (never; former; and smoker), 
alcohol consumption (g/d), dietary intakes related to cancer risk (energy, dietary fibre, fish and 
shellfish, meat and processed meat intake), self-reported diabetes at recruitment (yes; no), and 
menopausal hormone therapy (never; ever), for women only. Further adjustment for other risk factors 
was also tested such as dairy intake of calcium (g/d), but since no difference was observed in the HRs, 
these were excluded from the final models. For female-specific cancer sites (e.g. cancers of the 
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reproductive system) the models were further adjusted for menopausal status (premenopausal; 
postmenopausal; perimenopausal; and surgical postmenopausal) oral contraceptive use (never; ever), 
age at menarche (y) and age at first full-term pregnancy (y). Chi-squared tests were performed to 
evaluate whether the parameters of BMR and BMI for each cancer were significantly different (p-
heterogeneity). In an attempt to investigate the relationship between BMR and cancer risk, 
independent of BMI, BMR residuals were computed from a linear regression of BMR on BMI, height, 
age, country and sex. BMR residuals were normalised to 1-standard deviation and investigated in 
relation to cancer risk in multivariable Cox proportional hazards regression models, which were 
further adjusted for BMI. We also examined the relationship between BMR and cancer risk among 
normal weight (BMI<25 kg/m2) and overweight/obese groups (BMI≥25 kg/m2), and assessed 
heterogeneity between these subgroups and BMR by using interaction terms (multiplicative scale); the 
statistical significance of the cross-product terms was evaluated using the likelihood ratio test. This 
stratified analysis was also repeated using BMR residuals.  
All analyses were repeated separately according to menopausal status for female reproductive cancers. 
Women contributed person-time to the ‘premenopausal model’ until their age of menopause onset and 
from their age of menopause onwards to the ‘postmenopausal model’. Menopause age was collected 
at baseline for postmenopausal women. If missing, and if women were premenopausal at baseline, 
then menopause age was set as 55 years. Sensitivity analyses were performed excluding participants 
who self-reported chronic diseases (heart disease, diabetes, and stroke) and who self-reported weight 
and height at recruitment. The influence of preclinical disease on the results was assessed by 
excluding participants diagnosed within the first 2 years of follow-up. Statistical tests used in the 
analysis were all two-sided, and a p-value of <0.05 was considered as statistically significant. 
Statistical analyses were conducted using Stata v11.0 and the figures were constructed using R. 
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Data Availability 
EPIC data and biospecimens are available for investigators who seek to answer important questions 
on health and disease in the context of research projects that are consistent with the legal and ethical 
standard practices of IARC/WHO and the EPIC Centres. The primary responsibility for accessing the 
data belongs to the EPIC centres that provided them. The use of a random sample of anonymised data 
from the EPIC study can be requested by contacting epic@iarc.fr. The request will then be passed to 
members of the EPIC Steering Committee for deliberation. 
 
RESULTS 
A total of 141,295 men and 317,613 women with a mean age of 52 and 50 years at baseline, 
respectively, were included in the analysis. The mean follow-up time was 14 years (SD 4.0). Both 
male and female participants with higher BMR were taller, had higher BMI and reported greater 
intake of fish and shellfish and red and processed meat (Table 1). Male participants with higher BMR 
were more likely to report higher caloric and alcohol intake compared to those in the lowest category, 
while for female participants an opposite trend was observed. Female participants with higher BMR 
also had lower attained education level; earlier age at menarche and earlier age at first full pregnancy. 
Predicted BMR calculated using the WHO/FAO/UNU equation was strongly correlated (r>.96) with 
those derived from the other BMR equations. Correlation coefficients between predicted BMR and 
BMI were 0.53 among men and 0.77 among women (S2 Table). 
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The hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between BMR and 
risk for cancers at different anatomical sites, and their comparison with HRs and 95%CIs for the 
associations of cancer endpoints with BMI, are displayed in Figures 1 (men) and 2 (women). Results 
for colon cancer showed that a one standard deviation increase in BMR was associated with 29% 
(95%CI 1.21; 1.38) higher risk for men and 8% (95%CI 1.03; 1.13) higher risk for women (similar 
patterns of results were observed for proximal and distal colon cancers). For pancreatic cancer, a one 
standard deviation increase in BMR was associated with 13% (95%CI 1.01; 1.26) and 17% (95%CI 
1.08; 1.26) higher risk in men and women, respectively. Similarly, a one standard deviation increase 
in BMR was associated with an increased risk for kidney cancer in men (HR1-sd 1.40; 95%CI 1.25; 
1.55) and in women (HR1-sd 1.19; 95%CI 1.08; 1.30). For gallbladder cancer, one standard deviation 
increase in BMR was associated with 98% (95%CI 1.18; 3.32) higher risk in men and 31% (95%CI 
1.07; 1.61) higher risk in women. BMR was also positively associated with risks of stomach cardia 
(HR1-sd: 1.34, 95%CI 1.08; 1.67), meningioma (HR1-sd: 1.21, 95%CI 1.08; 1.35) and thyroid (HR1-sd: 
1.17, 95%CI 1.07; 1.28) cancers among women. For men, BMR was positively associated with risks 
of HCC (HR1-sd: 1.38; 95%CI 1.13; 1.68), esophageal adenocarcinoma (HR1-sd: 1.49; 95%CI 1.21; 
1.83), and multiple myeloma (HR1-sd: 1.15; 95%CI 1.05; 1.26). BMR remained statistically significant 
associated with most cancer sites when the multivariable models used BMR residuals and were 
further adjusted for BMI (Table 2). 
For female-specific cancers, one standard deviation increment in BMR was associated with a 8% 
(95%CI 1.08; 1.10) higher risk of breast cancer, 39% (95%CI 1.33; 1.47) higher risk of endometrial 
cancer, and 8% (95%CI 1.01; 1.15) higher risk of ovarian cancer. When these analyses were stratified 
by menopausal status, the associations were only evident among postmenopausal women (S3 Table).  
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The associations between BMI and risks of individual cancers were generally similar to those found 
for BMR (Figures 1 and 2). However, for breast cancer, compared to BMI, BMR was more strongly 
associated with risk (p-heterogeneity=0.014) (Figure 2). For cancers of the proximal colon (women 
only), stomach cardia, and thyroid (both men only) positive relationships were only found with BMR, 
but not with BMI; however, the heterogeneity did not meet the threshold of significance (p- 
heterogeneity>0.05) (Figures 1 and 2).  
BMR and Cancer Risk in Normal Weight and Overweight/Obese Groups 
Among normal weight participants (BMI<25 kg/m2), higher BMR was associated with elevated risks 
of esophageal adenocarcinoma (HR1-sd: 2.46; 95%CI 1.20; 2.03), and distal colon cancer (HR1-sd: 1.33; 
95%CI 1.001; 1.77) among men, and of proximal colon (HR1-sd: 1.16; 95%CI 1.01; 1.35), pancreatic 
(HR1-sd: 1.37; 95%CI 1.13; 1.66), thyroid (HR1-sd: 1.65; 95%CI 1.33; 2.05), breast (HR1-sd: 1.17; 
95%CI 1.11; 1.22), and endometrial (HR1-sd: 1.20; 95%CI 1.03; 1.40) cancers  among women (Table 
2). For overweight/obese men, BMR was positively related to risks of all cancers, although the 
positive relationships observed for stomach cardia, gallbladder, meningioma, thyroid and rectal 
cancers did not reach the threshold of significance. For overweight/obese women, BMR was 
positively and significantly associated with pancreatic (HR1-sd: 1.17; 95%CI 1.05; 1.31), kidney (HR1-
sd: 1.16; 95%CI 1.02; 1.32), breast (HR1-sd: 1.07; 95%CI 1.03; 1.11), endometrial (HR1-sd: 1.41; 95%CI 
1.31; 1.51), and ovarian (HR1-sd: 1.12; 95%CI 1.02; 1.24) cancers (Table 3). BMR remained 
statistically significantly associated with most cancer sites when the stratified analyses were repeated 
using BMR residuals (Table 4). When these analyses were stratified by menopausal status, the 
associations were only evident among postmenopausal women, even when using BMR residuals (S4 
Table). For the majority of cancer sites, there was no heterogeneity in the association of BMR with 
cancer risk among individuals with normal weight or with overweight or obesity. The exception was 
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for breast cancer, where higher BMR was more strongly associated with breast cancer among women 
with normal weight compared to those with overweight or obesity (P-heterogeneity=0.002). 
Sensitivity analysis 
The results were largely unchanged after cancer cases which occurred during the first 2 years of 
follow-up were excluded (S5 Tables). Also, sensitivity analyses excluding participants who self-
reported chronic diseases (S6 Tables) and who self-reported weight and height (S7 Tables) at 
recruitment showed similar results. 
DISCUSSION 
In this multi-country prospective cohort analysis, higher predicted BMR was associated with greater 
risk for most cancers that have been linked with obesity. Importantly, among normal-weight 
individuals (BMI<25kg/m2), higher BMR was associated with a greater risk of colon, pancreas, 
thyroid, esophageal adenocarcinoma, postmenopausal breast, and endometrial cancer. These results 
suggest that BMR may identify subgroups of the population who are at greater risk of these 
malignancies that would not have otherwise been identified solely by BMI.  
The reprogramming of energy metabolism is one of the hallmarks of cancer and metabolic 
transformation is a key event in tumorigenesis. Markers of metabolic health such as insulin regulation 
or of adiposity such as waist circumference and BMI are risk factors for a number of different 
cancers. In this analysis, we found that predicted BMR, which reflects whole body energy 
metabolism, was associated with the development of specific cancers, even among lean individuals. In 
terms of potential biological mechanisms, individuals with higher BMR require greater cellular 
energy generation to meet their higher energy and metabolic requirements. Enhanced aerobic 
glycolysis may lead to a greater reactive oxygen species (ROS) generation, a by-product of cellular 
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respiration. Although ROS production and detoxification are usually well balanced, a shift in this 
equilibrium may lead to ROS in excess promoting oxidative stress (28) and the accumulation of 
oncogenic DNA defects as well as the activation of oncogenic signalling pathways (29). In fact, a 
recent review suggested that higher BMR could increase cancer risk by means of higher oxidative 
stress and mutational rates (30). Increased ROS has also been linked to many metabolic alterations, 
such as insulin resistance (31), decreases in adiponectin and increased expression of pro-inflammatory 
cytokines including TNFα and IL-6 (32). In line with this, BMR has been positively associated with 
levels of insulin and Type 2 diabetes (33-35), although conflicting results have also been found (36, 
37). Previous studies have shown that these metabolic alterations can drive cancer development in 
both normal weight (4-7) and overweight individuals (33-35), which are in agreement with the results 
from the current study, showing that BMR was associated with cancer risk independent of BMI. 
The potential link between BMR and cancer may also explain why taller individuals have higher risk 
of certain cancers (38-41). Taller individuals have a greater requirement of energy metabolism due to 
a higher number of cells and organ mass. Although the underlying biological mechanisms are still not 
completely elucidated, it is suggested that the number of cells may influence the effect of height on 
cancer risk, as it would also increase the opportunities for mutations and malignant tumour 
development (42, 43). Higher exposure to growth hormones (GH) and insulin-like growth factor-1 
(IGF-1) during early growth, which might be activated by overnutrition during different stages of 
child development, may also be relevant (44-47), and it may differ by anatomical subsites (39).  
To our knowledge, this is the first investigation on the association between predicted measures of 
BMR and multiple cancers in a large-scale prospective cohort setting. The long term follow-up and 
high number of incident cancer cases recorded allowed us to investigate the BMR and cancer 
associations by sex and body size groups.  However, some limitations of the current study should also 
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be considered. First, BMR was only predicted and was assessed using WHO/FAO/UNU equations, 
which may overestimate actual BMR (8), particularly among overweight and obese individuals (48). 
This may occur as BMR equations take into account total body mass and do not make a distinction 
between lean and fat mass which differ metabolically. However, in our analysis BMR calculated 
using the WHO/FAO/UNU equation was strongly correlated with BMR predicted by Mufflin St Jean 
equation, which has been considered the most accurate for overweight and obese individuals (49). 
Although indirect calorimetry may be a more reliable tool to measure BMR, it is expensive compared 
to predictive equations and not realistic for large-scale population-based studies (9, 50). It is also 
important to note that only predicted BMR at baseline has been assessed in EPIC, while multiple 
measurements over time may allow a more precise assessment of the impact of BMR on cancer risk. 
Furthermore, the models were not adjusted for body fat-free mass, a factor that influences BMR (9), 
as this variable was not available. Another potential limitation is the quantity of missing data for self-
reported thyroid disease in EPIC, which is also an important factor that affects an individual’s BMR. 
However, given that only ~10% of the European population suffers from clinically manifest thyroid 
disease (51), it is unlikely that failure to capture this information would have substantially affected 
our results.  
Further, as BMR is a composite function of age, sex, height and weight, which are well known risk 
factors for cancer, it is possible that BMR may be capturing part of the effect of these variables on 
cancer. In an attempt to disentangle the association between predicted BMR and BMI, and to explore 
whether BMR captures additional information beyond BMI that may be relevant for cancer 
prediction, we repeated the analysis using BMR residuals and further adjusted the models by BMI or 
stratified them by BMI group. The results confirmed an association between BMR and cancer risk 
beyond adiposity. 
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In conclusion, higher predicted BMR was associated with most obesity-related malignancies and may 
be an indicator of a metabolic phenotype associated with cancer risk. Importantly, among normal-
weight individuals, higher BMR was related to greater risks of cancers of the colon, pancreas, thyroid, 
postmenopausal breast, endometrium, and esophageal adenocarcinoma. For these cancer sites, BMR 
may be a useful predictor of cancer risk regardless of overall adiposity. Further understanding of the 
role of metabolic dysfunction on cancer risk is needed. Additionally, the replication of these analyses 
using BMR measured by indirect calorimetry and adjusting for body composition (e.g. fat-mass and 
fat-free mass) could provide more robust evidence for the association between BMR and cancer risk.  
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Figure 1. Hazard ratio (HR) and 95% confidence intervals (CI) for cancer risk in relation to Basal 
Metabolic Rate (BMR) and Body Mass Index (BMI) in men  
Note. BMR: 1-standard deviation increase. BMI: 1-standard deviation increase. BMR and BMI estimates were derived from 
separate models. Cox proportional hazard regression models were stratified by center and age and adjusted for education, 
physical activity, smoking, alcohol consumption, dietary intake (energy intake, meat intake, fish and shellfish intake and 
fibre intake), self-reported diabetes at recruitment. *P-value for heterogeneity explored by chi-squared tests. 
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Figure 2. Hazard ratio (HR) and 95% confidence intervals (CI) for cancer risk in relation to Basal 
Metabolic Rate (BMR) and Body Mass Index (BMI) in women  
Note. BMR: 1-standard deviation increase. BMI: 1-standard deviation increase. BMR and BMI estimates were derived from 
separate models. Cox proportional hazard regression models were stratified by center and age and adjusted for education, 
physical activity, smoking, alcohol consumption, dietary intake (energy intake, meat intake, fish and shellfish intake and 
fibre intake), self-reported diabetes at recruitment, and hormonal replacement.*P-value for heterogeneity explored by chi-
squared tests. 
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Table 1. Baseline characteristics of EPIC participants by tertiles of BMR 
  All 
(N=458,908) 
Men (N=141,295)   Women (N=317,613) 
 
Tertile 1 Tertile 2 Tertile 3 
 
Tertile 1 Tertile 2 Tertile 3 
N(%) or 
Mean±SD 
N(%) or 
Mean±SD 
N(%) or 
Mean±SD 
N(%) or 
Mean±SD 
N(%) or 
Mean±SD 
N(%) or 
Mean±SD 
N(%) or 
Mean±SD 
Basal Metabolic Rate, kcal/d 1507±230.1 1591±117.1 1795±37.1 1972±104.3  1276±50.3 1372±22.9 1503±5.9 Age at recruitment, y 51±9.9 57±10.9 50±8.8 49±8.3  52±10.7 50±9.1 50±9.3 BMI, kg/m2  25.4±4.2  24.7±3.3 25.6±2.5 29.1±3.4   21.8±2.7 24.1±2.5 28.9±4.3  Height, m 1.66±.09 1.70±.06 1.74±.06 1.78±.06  1.59±.05 1.63±.06 1.65±.07 
Caloric intake, kcal/d  2076±620.9 2310±622.9 2433±658.4 2485±692.2  1938±530.6 1931±534.8 1913.±550.4 Total dietary fibre, g/d  23±7.7 23±8.3 24±8.4 24±8.4  22±7.5 22±7.4 22±7.3 Fish and shellfish, g/d  37±35.7 35±32.5 35±33.8 37±34.9  33±31.8 38±37.4 40±39.7 Red & processed meat, g/d  75±51.2 85±56.9 96±59.9 109±64.3  60±41.8 64±41.5 70±43.4 Alcohol, g/d  12±16.9 18±21.5 20±22.2 22±24.9  8±11.6 8±11.7 7±11.4 Smoking status 
        Never 222,996 (48.6) 15,593(33.1) 16,231 (34.4) 14,765 (31.3)  61,680 (58.2) 57,368 (54.2) 57,359 (54.2) Current 104,096 (22.7) 13,392 (28.4) 14,213 (30.2) 14,001 (29.7)  20,241 (19.1) 21,321 (20.1) 20,928 (19.7) Physical activity index 
        Inactive 95,451 (20.8) 11,534(24.5) 7,150 (15.2) 7,798 (16.5)  23,703 (22.4) 20,303(19.2) 24,963 (23.6) Active 83,215 (18.1) 9,856(20.9) 12,413 (26.4) 11,993 (25.5)  14,992 (14.1) 17,507 (16.5) 16,454 (15.5) Longer education 108,472 (23.9) 10,831 (23.3) 13,741 (29.4) 12,696 (27.1)  28,104 (27.0) 24,890 (23.9) 18,210 (17.4) 
         Diabetes 11,830 (2.8) 2,236 (5.4) 1,213 (2.7) 1,592 (3.6)  1,815 (1.8) 1,652 (1.7) 3,322(3.4) Menopausal status         Premenopausal 111,601 (24.3) - - -  36,088(34.0) 39,936(37.7) 35,577(33.6) Postmenopausal 136,239 (29.7) - - -  49,725(46.9) 41,521(39.2) 44,993(42.5) Oral contraceptives          
Never 127,549 (27.8) - - -  44,682(42.1) 39,005(36.9) 43,862(41.4) 
Current 181,707 (39.6) - - -  58,630(55.3) 63,940(60.4) 59,137(55.8) Hormone replacement          
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Never 221,453 (48.2) - - -  74,820(70.6) 73,242(69.2) 73,391(69.3) Current 51,335 (11.1) - - -  17,058(16.1) 17,951(16.9) 16,326(15.4) Age at menarche, y 13±1.5 - - -  13±1.5 13±1.5 13±1.5 Age at first full pregnancy, y 25±4.3 - - -  25±4.3 25±4.3 24±4.3 
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Table 2. Hazard ratio (HR) and 95% confidence intervals (CI) for cancer risk in relation to Basal 
Metabolic Rate residuals in men and women 
Cancer Site Men   Women 
HR (95%CI)   HR (95%CI) 
Esophageal 
adenocarcinoma 1.12 (0.94; 1.32)  1.05 (0.86; 1.29) 
Stomach cardia 1.16 (0.97; 1.37)  1.12 (0.97; 1.28) 
Colon 1.10 (1.05; 1.16)  1.05 (1.02; 1.07) 
Proximal Colon 1.12 (1.03; 1.21)  1.07 (1.04; 1.12) 
Distal Colon 1.13 (1.05; 1.22)  1.02 (0.98; 1.07) 
Rectal 0.96 (0.91; 1.03)  0.98 (0.94; 1.02) 
HCCa 0.88 (0.77; 1.00)  0.95 (0.82; 1.08) 
Gallbladder 1.36 (0.94; 1.96)  1.15 (1.01; 1.31) 
Pancreas 1.03 (0.95; 1.13)  1.10 (1.05; 1.16) 
Kidney 1.11 (1.02; 1.21)  1.01 (0.96; 1.08) 
Meningioma 0.84 (0.66; 1.05)  1.03 (0.96; 1.11) 
Thyroid 1.50 (1.16; 1.93)  1.13 (1.06; 1.20) 
Multiple Myeloma 1.07 (1.00; 1.15)  1.06 (1.02; 1.10) 
Breast -  1.05 (1.03; 1.07) 
Endometrium -  1.04 (1.01; 1.08) 
Ovarian 
 -  1.04 (0.99; 1.08) 
Note. BMR residual: 1-standard deviation increase. Models were stratified by center and age and adjusted for education, 
physical activity, smoking, alcohol consumption, dietary intake (energy intake, meat intake, fish and shellfish intake and 
fibre intake), self-reported diabetes at recruitment, hormonal replacement (for women only) and BMI. Additional adjustment 
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for menopause status, oral contraceptive, age at menarche and age at first full-term pregnancy for women-only cancer sites. 
aHepatocellular Carcinoma. 
 
 
 
Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) for cancer risk in relation to Basal 
Metabolic Rate (BMR) by body habitus status in men and women 
 Men  Women 
Cancer site Normal weight 
N or HR (95%CI) 
Overweight 
N or HR (95%CI) P* 
Normal weight 
N or HR (95%CI) 
Overweight 
N or HR (95%CI) P* 
Esophageal adenocarcinoma 
N◦ subj/cases 46,118/ 32 82,723/ 96  170,760/ 10 119,663/ 22  
BMR 2.46 (1.20; 5.03) 1.36 (1.05; 1.77) 0.094 1.05 (0.39; 2.82) 0.95 (0.60; 1.51) 0.919 
Stomach cardia 
N◦ subj/cases 46,118/ 45 82,723/ 92  170,760/ 27 119,663/ 41  
BMR  1.05 (0.59; 1.86) 1.24 (0.94; 1.65) 0.692 1.69 (.088; 3.24) 1.16 (0.85; 1.59) 0.173 
Colon        
N◦ subj/cases 46,118/382 82,723/ 1,031  170,760/ 1,035 119,663/ 1,051  
BMR 1.19 (0.98; 1.44) 1.30 (1.20; 1.41) 0.919 1.11 (1.00; 1.23) 1.07 (1.00; 1.14) 0.765 
Colon Proximal 
N◦ subj/cases 46,118/160 82,723/ 400  170,760/ 514 119,663/ 499  
BMR 1.19 (0.88; 1.58) 1.37 (1.20; 1.56) 0.375 1.16 (1.01; 1.35) 1.09 (0.99; 1.20) 0.575 
Colon Distal 
N◦ subj/cases 46,118/171 82,723/ 400  170,760/ 418 119,663/ 424  
BMR 1.33 (1.00; 1.77) 1.29 (1.15; 1.46) 0.535 1.05 (0.88; 1.24) 1.05 (0.95; 1.17) 0.743 
Rectal       
N◦ subj/cases 46,118/288 82,723/ 678  170,760/ 506 119,663/ 446  
BMR 0.99 (0.79; 1.23) 1.03 (0.92; 1.14) 0.964 1.10 (0.94; 1.28) 1.004 (0.90; 1.11) 0.606 
HCCa       
N◦ subj/cases 46,118/ 34 82,723/ 107  170,760/ 25 119,663/ 39  
BMR  0.95 (0.50; 1.80) 1.48 (1.17; 1.88) 0.260 1.01 (0.52; 1.95) 0.95 (0.66; 1.37) 0.379 
Gallbladder       
N◦ subj/cases 46,118/ 4 82,723/ 18  170,760/ 29 119,663/ 56  
BMR  -¥ 1.43 (0.76; 2.71) 0.079 1.38 (0.70; 2.70) 1.25 (0.96; 1.65)  0.639 
Pancreas       
N◦ subj/cases 46,118/167 82,723/362  170,760/ 5312 119,663/ 334  
BMR  0.98 (0.73; 1.33) 1.18 (1.03; 1.37) 0.501 1.37 (1.13; 1.66) 1.17 (1.05; 1.31) 0.595 
Kidney       
N◦ subj/cases 46,118/ 130 82,723/ 378  170,760/ 190 119,663/ 244  
BMR  1.21 (0.86; 1.68) 1.42 (1.24; 1.62) 0.455 1.13 (0.88; 1.46) 1.16 (1.02; 1.32) 0.922 
Meningioma       
N◦ subj/cases 46,118/ 22 82,723/ 47  170,760/ 134 119,663/ 184  
BMR  0.27 (0.10; .68) 1.19 (0.77; 1.84) 0.259 1.20 (0.86; 1.67) 1.10 (0.94; 1.29) 0.898 
Thyroid       
N◦ subj/cases 46,118/ 26 82,723/ 60  170,760/ 321 119,663/ 260  
BMR  1.38 (0.63; 3.06) 1.26 (0.87; 1.83) 0.376 1.65 (1.33; 2.05) 1.04 (0.90; 1.20) 0.002 
Multiple Myeloma 
N◦ subj/cases 46,118/ 272 82,723/ 536  170,760/ 586 119,663/ 485  
BMR  1.12 (0.89; 1.41) 1.26 (1.12; 1.41) 0.669 1.07 (0.93; 1.24) 1.08 (0.98; 1.19) 0.743 
Breast        
N◦ subj/cases - -  130,681/ 6,196 101,445/4,462  
BMR  - -  1.17 (1.11; 1.22) 1.07 (1.03; 1.11) 0.002 
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Endometrium       
N◦ subj/cases - -  130,681/ 553 101,445/ 779  
BMR  - -  1.20 (1.03; 1.40) 1.41 (1.31; 1.51) 0.123 
Ovary       
N◦ subj/cases - -  130,681/ 527 101,445/ 457  
BMR  - -  1.10 (0.94; 1.29) 1.12 (1.02; 1.24) 0.766 
Note. BMR: 1-standard deviation increase. Models were stratified by center and age and adjusted for education, physical 
activity, smoking, alcohol consumption, dietary intake (energy intake, meat intake, fish and shellfish intake and fibre intake), 
self-reported diabetes at recruitment, and hormonal replacement (for women only). Additional adjustment for menopause 
status, oral contraceptive, age at menarche and age at first full-term pregnancy for women-only cancer sites. *P-value for 
heterogeneity explored by modelling interaction terms between BMR and BMI group. aHepatocellular Carcinoma. Normal 
weight= BMI between 18.5 and 24.9 kg/m2. Overweight= BMI 25 kg/m2 or over. ¥No sufficient cases. 
 
 
Table 4. Hazard ratio (HR) and 95% confidence intervals (CI) and cancer risk in relation to Basal 
Metabolic Rate residuals (BMR residuals) by body fatness status in men and women 
 Men  Women 
Cancer site Normal weight 
N or HR (95%CI) 
Overweight 
N or HR (95%CI) P* 
Normal weight 
N or HR (95%CI) 
Overweight 
N or HR (95%CI) P* 
Esophageal adenocarcinoma 
N◦ subj/cases 46,118/ 32 82,723/ 96  170,760/ 10 119,663/ 22  
BMR residuals 1.58 (1.10; 2.28) 1.17 (1.02; 1.34) 0.433 1.01 (0.73; 1.41) 0.98 (0.84; 1.14) 0.058 
Stomach cardia 
N◦ subj/cases 46,118/ 45 82,723/ 92  170,760/ 27 119,663/ 41  
BMR residuals 1.03 (0.76; 1.37) 1.11 (0.97; 1.29) 0.622 1.19 (0.96; 1.47) 1.05 (0.94; 1.16) 0.593 
Colon        
N◦ subj/cases 46,118/382 82,723/ 1,031  170,760/ 1,035 119,663/ 1,051  
BMR residuals 1.09 (0.99; 1.20) 1.14 (1.09; 1.19) 0.656 1.03 (1.00; 1.07) 1.02 (1.00; 1.04) 0.577 
Colon Proximal 
N◦ subj/cases 46,118/160 82,723/ 400  170,760/ 514 119,663/ 499  
BMR residuals 1.09 (0.94; 1.26) 1.17 (1.09; 1.25) 0.972 1.05 (1.00; 1.10) 1.03 (0.99; 1.06) 0.223 
Colon Distal 
N◦ subj/cases 46,118/171 82,723/ 400  170,760/ 418 119,663/ 424  
BMR residuals 1.15 (1.00; 1.34) 1.14 (1.07; 1.21) 0.938 1.01 (0.96; 1.07) 1.01 (0.98; 1.05) 0.833 
Rectal       
N◦ subj/cases 46,118/288 82,723/ 678  170,760/ 506 119,663/ 446  
BMR residuals 0.99 (0.88; 1.11) 1.01 (0.96; 1.07) 0.287 1.03 (0.98; 1.08) 1.001 (0.97; 1.03) 0.964 
HCCa       
N◦ subj/cases 46,118/ 34 82,723/ 107  170,760/ 25 119,663/ 39  
BMR residuals 0.97 (0.70; 1.35) 1.22 (1.08; 1.38) 0.645 1.003 (0.80; 1.24) 0.98 (0.87; 1.11) 0.476 
Gallbladder       
N◦ subj/cases 46,118/ 4 82,723/ 18  170,760/ 29 119,663/ 56  
BMR residuals -¥ 1.20 (0.86; 1.66) - 1.11 (0.89; 1.38) 1.07 (0.98; 1.18)  0.795 
Pancreas       
N◦ subj/cases 46,118/167 82,723/362  170,760/ 5312 119,663/ 334  
BMR residuals 0.99 (0.85; 1.15) 1.09 (1.01; 1.17) 0.956 1.11 (1.04; 1.18) 1.05 (1.01; 1.09) 0.097 
Kidney       
N◦ subj/cases 46,118/ 130 82,723/ 378  170,760/ 190 119,663/ 244  
BMR residuals 1.10 (0.93; 1.30) 1.19 (1.11; 1.28) 0.688 1.04 (.95; 1.13) 1.05 (1.00; 1.09) 0.374 
Meningioma       
N◦ subj/cases 46,118/ 22 82,723/ 47  170,760/ 134 119,663/ 184  
BMR residuals 0.51 (0.32; 0.82) 1.09 (0.87; 1.36) 0.244 1.06 (0.95; 1.18) 1.03 (0.97; 1.09) 0.067 
Thyroid       
N◦ subj/cases 46,118/ 26 82,723/ 60  170,760/ 321 119,663/ 260  
BMR residuals 1.18 (0.78; 1.77) 1.12 (0.93; 1.36) 0.911 1.18 (1.10; 1.26) 1.01 (0.96; 1.06) 0.413 
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Multiple Myeloma 
N◦ subj/cases 46,118/ 272 82,723/ 536  170,760/ 586 119,663/ 485  
BMR residuals 1.06 (0.94; 1.19) 1.12 (1.06; 1.19) 0.013 1.02 (0.97; 1.07) 1.02 (0.99; 1.06) 0.522 
Breast        
N◦ subj/cases - -  130,681/ 6,196 101,445/4,462  
BMR residuals - -  1.05 (1.03; 1.07) 1.02 (1.01; 1.03) 0.009 
Endometrium       
N◦ subj/cases - -  130,681/ 553 101,445/ 779  
BMR residuals - -  1.06 (1.01; 1.11) 1.12 (1.09; 1.14) 0.402 
Ovary       
N◦ subj/cases - -  130,681/ 527 101,445/ 457  
BMR residuals - -  1.03 (0.97; 1.09) 1.04 (1.00; 1.07) 0.170 
Note. BMR residual: 1-standard deviation increase. Models were stratified by center and age and adjusted for education, 
physical activity, smoking, alcohol consumption, dietary intake (energy intake, meat intake, fish and shellfish intake and 
fibre intake), self-reported diabetes at recruitment, hormonal replacement (for women only) and BMI. Additional adjustment 
for menopause status, oral contraceptive, age at menarche and age at first full-term pregnancy for women-only cancer sites. 
*P-value for heterogeneity explored by modelling interaction terms between BMR and BMI group. aHepatocellular 
Carcinoma. Normal weight= BMI between 18.5 and 24.9 kg/m2. Overweight= BMI 25 kg/m2 or over. ¥No sufficient cases. 
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Although the basal metabolic rate (BMR) –defined as the daily rate of energy metabolism required to preserve vital 
functions– has been associated with increased breast cancer risk, its relevance in other cancers remains unknown. 
Here, the authors examined associations with 13 cancers in over 500,000 individuals in Europe. Among normal-
weight individuals, BMR was positively associated with cancers of the colon, pancreas, thyroid, esophageal 
adenocarcinoma, postmenopausal breast, and endometrium, pointing to BMR as a way to identify subgroups of the 
population who are at greater risk of these malignancies.   
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